-

08:38:04 AM

Latest EIGR Stock Market News

EIGR - Eiger BioPharmaceuticals Inc

09/21/21 8:00 AM

Nasdaq : EIGR

management

Eiger BioPharmaceuticals Appoints Erik Atkisson as General Counsel and Chief Compliance Officer

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced the appointment of Erik

RHEA-AI

neutral

09/20/21 8:00 AM

Nasdaq : EIGR

clinical trialcovid-19

Eiger BioPharmaceuticals Announces Interim Analysis and Continuation of Dosing of Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the Data Safety

RHEA-AI

neutral

09/01/21 4:05 PM

Nasdaq : EIGR

conferences

Eiger BioPharmaceuticals to Participate in Upcoming September 2021 Investor Conferences

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President

RHEA-AI

neutral

08/05/21 4:01 PM

Nasdaq : EIGR

earnings

Eiger BioPharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported its second quarter 2021

RHEA-AI

very positive

08/05/21 8:00 AM

Nasdaq : EIGR

Eiger Announces FDA Breakthrough Therapy Designation for Avexitide for Treatment of Congenital Hyperinsulinism

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug

RHEA-AI

neutral

08/03/21 4:05 PM

Nasdaq : EIGR

conferences

Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and

RHEA-AI

neutral

07/22/21 4:05 PM

Nasdaq : EIGR

conferencesearnings

Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2021 Financial Results and Business Update on Thursday, August 5

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it will host a

RHEA-AI

neutral

07/07/21 8:00 AM

Nasdaq : EIGR

conferences

Eiger BioPharmaceuticals to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and

RHEA-AI

neutral

07/06/21 8:00 AM

Nasdaq : EIGR

clinical trialcovid-19

Eiger BioPharmaceuticals Announces First Patients Dosed with Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the first patients were

RHEA-AI

neutral

07/02/21 4:05 PM

Nasdaq : EIGR

Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported the grant of a stock option to

RHEA-AI

very positive